Correction: Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)

• Huei-Jen Chen,
• Yi-An Cheng,
• Yu-Tung Chen,
• Chia-Ching Li,
• Bo-Cheng Huang,
• Shih-Ting Hong,
• I.-Ju Chen,
• Kai-Wen Ho,
• Chiao-Yun Chen,
• Fang-Ming Chen,
• Jaw-Yuan Wang,
• Steve R. Rofer,
• Tian-Lu Cheng,
• Tung-Ho Wu

Affiliations

Huei-Jen Chen

Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University

Yi-An Cheng

Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University

Yu-Tung Chen

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University

Chia-Ching Li

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University

Bo-Cheng Huang

Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University

Shih-Ting Hong

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University

I.-Ju Chen

Drug Development and Value Creation Research Center, Kaohsiung Medical University

Kai-Wen Ho

Drug Development and Value Creation Research Center, Kaohsiung Medical University

Chiao-Yun Chen

Drug Development and Value Creation Research Center, Kaohsiung Medical University

Fang-Ming Chen

Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital

Jaw-Yuan Wang

Drug Development and Value Creation Research Center, Kaohsiung Medical University

Steve R. Rofer

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University

Tian-Lu Cheng

Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University

Tung-Ho Wu

Department of Cardiovascular Surgeon, Kaohsiung Veterans General Hospital